Evidence map›Paper›PMID 39155352›Full record

ArticleJournal of neurovirology2024

Progressive multifocal leukoencephalopathy in sarcoidosis successfully treated with pembrolizumab.

Gizem Öztürk, Elif İrem Tekeli, Seyda Erdoğan, Elif Peker, Canan Yücesan

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Journal of neurovirology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gizem ÖztürkDepartment of Neurology, Ankara University School of Medicine, Ibn-i Sina Hospital, Ankara, 06230, Türkiye. ozturkgizem96@gmail.com.ORCID 0000-0002-8743-4412
Elif İrem TekeliDepartment of Neurology, Ankara University School of Medicine, Ibn-i Sina Hospital, Ankara, 06230, Türkiye.
Seyda ErdoğanDepartment of Neurology, Ankara University School of Medicine, Ibn-i Sina Hospital, Ankara, 06230, Türkiye.
Elif PekerDepartment of Radiology, Ankara University School of Medicine, İbni Sina Hospital, Ankara, 06230, Türkiye.
Canan YücesanDepartment of Neurology, Ankara University School of Medicine, Ibn-i Sina Hospital, Ankara, 06230, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progressive multifocal leukoencephalopathy (PML) is a severe, demyelinating disease of the central nervous system caused by JC virus infection. The disease can be seen in sarcoidosis patients without additional risk factors. Here, we present an individual with PML secondary to sarcoidosis treated with 8 doses of pembrolizumab, a Programmed Cell-Death-1 (PD-1) Immune Checkpoint Inhibitor who showed significant improvement. This report illustrates the objective clinical and radiological improvement in a patient with PML due to sarcoidosis, and suggests further study of immune checkpoint inhibitors as a potential treatment for sarcoidosis patients with PML.

Indexed as

Antibodies, Monoclonal, HumanizedLeukoencephalopathy, Progressive MultifocalSarcoidosisFemaleHumansImmune Checkpoint InhibitorsJC VirusMaleMiddle AgedTreatment OutcomeAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorspembrolizumabJC VirusPembrolizumabPML with sarcoidosisProgressive multifocal leukoencephalopathy

Identifiers

PMID39155352

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.